home / stock / galt / galt quote
Last: | $2.72 |
---|---|
Change Percent: | 0.0% |
Open: | $2.72 |
Close: | $2.72 |
High: | $2.82 |
Low: | $2.7 |
Volume: | 91,911 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.72 | $2.72 | $2.72 | $2.82 | $2.7 | 91,911 | 05-31-2024 |
$2.72 | $2.78 | $2.72 | $2.93 | $2.71 | 101,085 | 05-30-2024 |
$2.79 | $2.8 | $2.79 | $2.87 | $2.77 | 99,416 | 05-29-2024 |
$2.82 | $3.04 | $2.82 | $3.12 | $2.75 | 272,005 | 05-28-2024 |
$3.05 | $3 | $3.05 | $3.1 | $2.95 | 120,671 | 05-27-2024 |
$3.05 | $3 | $3.05 | $3.1 | $2.95 | 120,671 | 05-24-2024 |
$3.05 | $3.09 | $3.05 | $3.16 | $2.99 | 78,873 | 05-23-2024 |
$3.11 | $3.18 | $3.11 | $3.2799 | $3.08 | 93,271 | 05-22-2024 |
$3.23 | $3.18 | $3.23 | $3.28 | $3.11 | 76,570 | 05-21-2024 |
$3.16 | $3.2 | $3.16 | $3.28 | $3.06 | 158,602 | 05-20-2024 |
$3.23 | $3.18 | $3.23 | $3.26 | $3.15 | 148,564 | 05-17-2024 |
$3.14 | $3.07 | $3.14 | $3.17 | $3.05 | 79,209 | 05-16-2024 |
$3.06 | $2.78 | $3.06 | $3.12 | $2.78 | 136,424 | 05-15-2024 |
$2.84 | $3.09 | $2.84 | $3.1 | $2.8 | 170,602 | 05-14-2024 |
$3.08 | $3.05 | $3.08 | $3.08 | $2.75 | 278,102 | 05-13-2024 |
$3.03 | $3.25 | $3.03 | $3.2842 | $2.92 | 288,595 | 05-10-2024 |
$3.25 | $3.26 | $3.25 | $3.41 | $3.15 | 120,986 | 05-09-2024 |
$3.24 | $3.35 | $3.24 | $3.38 | $3.2 | 138,401 | 05-08-2024 |
$3.35 | $3.46 | $3.35 | $3.55 | $3.33 | 145,836 | 05-07-2024 |
$3.47 | $3.36 | $3.47 | $3.59 | $3.3 | 151,201 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Galectin Therapeutics Inc. Company Name:
GALT Stock Symbol:
NASDAQ Market:
Galectin Therapeutics Inc. Website:
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-lin...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target gale...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference. Detai...